All In Biotech

Drug Trial Radar · NCT06852963

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 (30 μg and 75 μg) Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 in the PLATYPUS Study (Protocol # VP001-101) or WALLABY Study (Protocol # VP001-102) for a Minimum of 8 Weeks

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

17

Actual

Start

Jun 1, 2025

Primary completion

Mar 8, 2028

Study completion Apr 21, 2028

Sponsor

Lead sponsor
PYC TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31 mutation-associated retinal dystrophy, including participants previously treated with VP001 in the PLATYPUS Study or WALLABY Study for a minimum of 8 weeks.

Conditions

  • Retinitis Pigmentosa 11
  • Retinal Degeneration
  • Retinal Disease
  • Eye Diseases Hereditary
  • Retinal Dystrophies

Interventions

  • VP-001Drug

    VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy.Time frame: 26 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida College of Medicine

    Jacksonville, Florida

  • Bascom Palmer Eye Institute - University of Miami

    Miami, Florida

  • Kellogg Eye Center - University of Michigan

    Ann Arbor, Michigan

  • Casey Eye Institute - OHSU

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.